




Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > For curative treatment

| | | EMLc | ATC codes: P01BE02 |
|-------------------------|--|----------------------------------|------------------------------------|
| Indication | Malaria due to Plasmodium falciparum | ICD11 code: 1F40 | |
| INN | Artemether | | |
| Medicine type | Chemical agent | | |
| List type | Core For use in the management of severe malaria | | |
| Formulations | Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection) | | |
| EML status history | First added in 1997 (TRS 882) Changed in 2002 (TRS 914) Changed in 2007 (TRS 946) Changed in 2007 (TRS 950) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic equivalence | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Wikipedia | Artemether  | | |
| DrugBank | Artemether  | | |

Summary of evidence and Expert Committee recommendations

Artemether was added to the core list of the EMLc for the curative treatment of malaria.

